MedTrace Logo

Effect of Low Dose Aspirin on Birthweight in Twins: The GAP Trial.

NCT02280031 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2018-11-09

No results posted yet for this study

Summary

Low-dose aspirin started in the first-trimester has been associated with a decrease of preeclampsia, fetal growth restriction and preterm birth in high-risk pregnancies. Multiple pregnancies are considered a risk factor for all those adverse outcomes. The main objective of the current trial is to evaluate whether a dose of 80 mg of aspirin is associated with an improvement of birthweight compared to placebo in twin pregnancies.

Conditions

  • Small for Gestational Age
  • Infant, Very Low Birth Weight
  • Fetal Growth Retardation
  • Preeclampsia
  • Premature Birth

Interventions

DRUG

Acetylsalicylic Acid

Capsule containing Acetylsalicylic Acid 80mg pill with lactose

DRUG

Placebo

Capsule containing placebo pill with lactose

Sponsors & Collaborators

  • CHU de Quebec-Universite Laval

    lead OTHER

Principal Investigators

  • Emmanuel Bujold, MD,MSc,FRCSC · CHU de Québec

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2014-11-30
Primary Completion
2016-10-31
Completion
2016-11-30

Countries

  • Canada

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02280031 on ClinicalTrials.gov